Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
NCT06258668 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 505
Last updated 2024-11-06
Summary
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Conditions
- Moderate-to-severe Plaque Psoriasis
Interventions
- DRUG
-
As per product label
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-21
- Primary Completion
- 2028-09-30
- Completion
- 2028-09-30
- FDA Drug
- Yes
Countries
- South Korea
Study Locations
More Related Trials
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967 ·Status: RECRUITING ·Phase: PHASE3
-
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
NCT06973291 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
NCT01412944 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
NCT06952465 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
NCT04433442 ·Status: COMPLETED
-
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
NCT05478499 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
NCT01365455 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
NCT04316585 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT04772079 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
NCT05020249 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
NCT00747344 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Secukinumab in Mild Psoriasis
NCT03131570 ·Status: COMPLETED ·Phase: PHASE2
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
NCT06176508 ·Status: RECRUITING ·Phase: PHASE2
-
Correction of Psoriatic T Cell Signatures by Deucravacitinib
NCT05858645 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
NCT05730725 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
NCT02595970 ·Status: COMPLETED ·Phase: PHASE3
-
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
NCT07243782 ·Status: RECRUITING
-
Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis
NCT06058546 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
NCT06042920 ·Status: TERMINATED ·Phase: PHASE4
-
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
NCT06142357 ·Status: ACTIVE_NOT_RECRUITING
-
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
NCT05744466 ·Status: RECRUITING
-
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
NCT02413229 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
NCT03066609 ·Status: COMPLETED ·Phase: PHASE3
-
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
NCT06701513 ·Status: RECRUITING